New liquid biopsy-based cancer model reveals data on deadly lung cancer

April 15, 2018, University of Texas M. D. Anderson Cancer Center

Small cell lung cancer (SCLC) accounts for 14 percent of all lung cancers and is often rapidly resistant to chemotherapy resulting in poor clinical outcomes. Treatment has changed little for decades, but a study at The University of Texas MD Anderson Cancer Center offers a potential explanation for why the disease becomes chemoresistant, and a possible avenue to explore new diagnostic approaches.

Findings from the study were presented today, at the American Association for Cancer Research Annual Meeting 2018 in Chicago by Allison Stewart, Ph.D., Research Scientist in Thoracic Head & Neck Medical Oncology.

"There have been few therapeutic advances in the past 30 years and remains the standard of care. As a result, five-year survival is less than 7 percent across all stages," said Lauren Byers, M.D., associate professor of Thoracic Head & Neck Medical Oncology, and the study's principle investigator. "Most patients respond well to platinum initially, but relapse within a few months. There are no highly effective second-line therapies."

The challenge in studying why and how SCLC chemoresistance occurs is due to the fact that most patients do not undergo another biopsy or surgery at the time of cancer recurrence. This leaves investigators like Byers and Stewart with few SCLC samples with which to conduct genomic and biomarker analyses of drug-resistant tumors.

To overcome the lack of SCLC samples, the team developed novel disease models by isolating circulating from a simple blood draw. The , placed under the mouse's skin, develop tumors representative of the patient from whom they were derived. These SCLC models, called circulating cell-derived xenografts (CDX), are unique to each patient and provide an opportunity to assess treatment response to novel targeted therapies, as well as changes that may occur in response to therapy.

"We hypothesize that differences in gene and protein expression between tumor cells, called intratumoral heterogeneity, contribute to the rapid development of platinum chemotherapy resistance," said Stewart. "This means that there are likely multiple cell populations in SCLC patients who have not yet been treated. Some of those cells may be killed by chemotherapy but others will not. These resistant cells then continue to grow and prevent further response to treatment."

To study intratumoral heterogeneity (ITH) in SCLC, the investigators performed single-cell sequencing of CDX models to identify gene expression differences between individual cells from chemotherapy-sensitive CDX tumors compared to those that remain resistant.

"We conducted single-cell RNA sequencing to determine if ITH exists and to compare response to chemotherapy in the CDX and the patient," said Stewart. "We found several distinctions between sensitive and resistant models detected at the single-cell level, which testified to single cell sequencing's potential usefulness for understanding how these cancers may develop resistance."

SCLC has a variety of differences at the cellular and genetic level, from the way genes are expressed to which cell-signaling pathways are involved. These differences between tumor cells result in ITH. A more thorough understanding of ITH is important to identify populations of cells that may drive certain pathways associated with aggressive resistance to chemotherapy.

The team also found that SCLC models sensitive to chemotherapy had more cells that expressed two genes, ASCL1 and DLL3, while those that were chemoresistant had fewer cells expressing those genes or had undergone a process called epithelial-to-mesenchymal transition (EMT), which also has been shown to play a role in therapy resistance in other cancers.

"Cells expressing each of these characteristics were identified across all tumors, suggesting cells sensitive or resistant to chemotherapy are both present in the same tumor," said Stewart. "However, even subtle shifts in the distribution of these genes can exert significant impact on response to treatment."

Stewart adds that the team's data support further use of single-cell analysis to explore the role of ITH in SCLC, including effects of treatment on cell populations.

"Through use of these new mouse models, we report data that supports use of single-cell analysis to explore the role of ITH as a driver of drug resistance," said Stewart.

Explore further: Study identifies a potential therapeutic target for lung cancer

Related Stories

Study identifies a potential therapeutic target for lung cancer

June 13, 2016
Small-cell lung cancer (SCLC) is one of the deadliest types of cancer, and it has been several decades since new treatment options have been approved for this disease. Although recent advances in cancer treatments have focused ...

Technique identifies chemotherapy-resistant cells within acute myeloid leukemia tumors

September 6, 2016
Although chemotherapy can sometimes cure acute myeloid leukemia and other hematologic cancers, many patients experience relapses when their tumors become resistant to available chemotherapies. This resistance may be caused ...

Cause of chemoresistance in small cell lung cancer discovered

July 18, 2017
Approximately one year after successful treatment with cytotoxic chemotherapy and radiotherapy, patients with advanced Small Cell Lung Cancer (SCLC), which primarily affects heavy smokers, generally relapse with recurrence ...

Chemotherapy helps elderly patients with small cell lung cancer

September 4, 2013
Although numerous randomized clinical trials have demonstrated a benefit of chemotherapy for patients with small-cell lung cancer (SCLC), these trials have predominantly compared different chemotherapy regimens rather than ...

Novel oncogenic RET mutation found in small cell lung cancer

August 22, 2014
For the first time an oncogenic somatic mutation at amino acid 918 in the RET (rearranged during transfection) protein has been identified in small cell lung cancer (SCLC) tumors and enforced expression of this mutation within ...

Newly discovered clues to the cause of chemoresistance in small cell lung cancer

April 4, 2016
Small cell lung cancer is not usually detected until it is at an advanced stage, when metastases have already formed. Chemotherapy is very effective initially but, within a year, cancer recurs and this time does not respond ...

Recommended for you

Single-cell study in a childhood brain tumor affirms the importance of context

April 20, 2018
In defining the cellular context of diffuse midline gliomas, researchers find the cells fueling their growth and suggest a potential approach to treating them: forcing their cells to be more mature.

Aggressive breast cancer already has resistant tumour cells prior to chemotherapy

April 20, 2018
Difficult to treat and aggressive "triple-negative" breast cancer is chemoresistant even before chemotherapy begins, a new study by researchers from Karolinska Institutet and the University of Texas MD Anderson Cancer Center ...

Mechanism that drives development of liver cancer brought on by non-alcoholic fatty liver disease discovered

April 19, 2018
A team of researchers from several institutions in China has found a mechanism that appears to drive the development of a type of liver cancer not caused by alcohol consumption. In their paper published in the journal Science ...

Discovery adds to evidence that some children are predisposed to develop leukemia

April 19, 2018
St. Jude Children's Research Hospital researchers have made a discovery that expands the list of genes to include when screening individuals for possible increased susceptibility to childhood leukemia. The finding is reported ...

Chip-based blood test for multiple myeloma could make bone biopsies a relic of the past

April 19, 2018
The diagnosis and treatment of multiple myeloma, a cancer affecting plasma cells, traditionally forces patients to suffer through a painful bone biopsy. During that procedure, doctors insert a bone-biopsy needle through an ...

Scientists identify 170 potential lung cancer drug targets using unique cellular library

April 19, 2018
After testing more than 200,000 chemical compounds, UT Southwestern's Simmons Cancer Center researchers have identified 170 chemicals that are potential candidates for development into drug therapies for lung cancer.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.